Research ExplorerPublicationsAllogeneic stem cell transplantation for myelofibrosis with ...

Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation

Standard

Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation. / Alchalby, Haefaa; Zabelina, Tatjana; Stübig, Thomas; van Biezen, Anja; Bornhäuser, Martin; Di Bartolomeo, Paolo; Beelen, Dietrich; Cahn, Jean Yves; Dreger, Peter; Schroyens, William; de Witte, Theo; Olavarria, Eduardo; Kröger, Nicolaus; Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

In: BIOL BLOOD MARROW TR, Vol. 20, No. 2, 01.02.2014, p. 279-81.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Alchalby, H, Zabelina, T, Stübig, T, van Biezen, A, Bornhäuser, M, Di Bartolomeo, P, Beelen, D, Cahn, JY, Dreger, P, Schroyens, W, de Witte, T, Olavarria, E, Kröger, N & Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT) 2014, 'Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation', BIOL BLOOD MARROW TR, vol. 20, no. 2, pp. 279-81. https://doi.org/10.1016/j.bbmt.2013.10.027

APA

Alchalby, H., Zabelina, T., Stübig, T., van Biezen, A., Bornhäuser, M., Di Bartolomeo, P., Beelen, D., Cahn, J. Y., Dreger, P., Schroyens, W., de Witte, T., Olavarria, E., Kröger, N., & Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT) (2014). Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation. BIOL BLOOD MARROW TR, 20(2), 279-81. https://doi.org/10.1016/j.bbmt.2013.10.027

Vancouver

Alchalby H, Zabelina T, Stübig T, van Biezen A, Bornhäuser M, Di Bartolomeo P et al. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation. BIOL BLOOD MARROW TR. 2014 Feb 1;20(2):279-81. https://doi.org/10.1016/j.bbmt.2013.10.027

Bibtex

@article{3afc17ec9e484971b5f542682bd1f027,
title = "Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation",
abstract = "Transformed acute myeloid leukemia in myelofibrosis results in a median survival of less than 5 months. We identified 46 of 1048 myelofibrosis patients in the European Group for Blood and Marrow Transplantation registry who received allogeneic stem cell transplantation for acute leukemia evolving from myelofibrosis. The cumulative incidence of treatment-related mortality at 1 year was 28% (95% confidence interval, 14 to 42) and of relapse at 3 years was 47% (95% confidence interval, 31 to 63). The 3-year progression-free (PFS) and overall survival (OS) rates were 26% and 33%, respectively. The only significant factor for survival was complete remission versus no complete remission before transplantation (69% versus 22%, P = .008); however, complete remission was achieved only in 8 patients. Allogeneic stem cell transplantation can cure myelofibrosis patients transformed to leukemia.",
keywords = "Adult, Aged, Cohort Studies, Europe, Female, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Male, Middle Aged, Myeloproliferative Disorders, Neoplasm Recurrence, Local, Primary Myelofibrosis, Remission Induction, Transplantation Conditioning, Transplantation, Autologous",
author = "Haefaa Alchalby and Tatjana Zabelina and Thomas St{\"u}big and {van Biezen}, Anja and Martin Bornh{\"a}user and {Di Bartolomeo}, Paolo and Dietrich Beelen and Cahn, {Jean Yves} and Peter Dreger and William Schroyens and {de Witte}, Theo and Eduardo Olavarria and Nicolaus Kr{\"o}ger and {Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT)}",
note = "Copyright {\textcopyright} 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.",
year = "2014",
month = feb,
day = "1",
doi = "10.1016/j.bbmt.2013.10.027",
language = "English",
volume = "20",
pages = "279--81",
journal = "BIOL BLOOD MARROW TR",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "2",

}

RIS

TY - JOUR

T1 - Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation

AU - Alchalby, Haefaa

AU - Zabelina, Tatjana

AU - Stübig, Thomas

AU - van Biezen, Anja

AU - Bornhäuser, Martin

AU - Di Bartolomeo, Paolo

AU - Beelen, Dietrich

AU - Cahn, Jean Yves

AU - Dreger, Peter

AU - Schroyens, William

AU - de Witte, Theo

AU - Olavarria, Eduardo

AU - Kröger, Nicolaus

AU - Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

N1 - Copyright © 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

PY - 2014/2/1

Y1 - 2014/2/1

N2 - Transformed acute myeloid leukemia in myelofibrosis results in a median survival of less than 5 months. We identified 46 of 1048 myelofibrosis patients in the European Group for Blood and Marrow Transplantation registry who received allogeneic stem cell transplantation for acute leukemia evolving from myelofibrosis. The cumulative incidence of treatment-related mortality at 1 year was 28% (95% confidence interval, 14 to 42) and of relapse at 3 years was 47% (95% confidence interval, 31 to 63). The 3-year progression-free (PFS) and overall survival (OS) rates were 26% and 33%, respectively. The only significant factor for survival was complete remission versus no complete remission before transplantation (69% versus 22%, P = .008); however, complete remission was achieved only in 8 patients. Allogeneic stem cell transplantation can cure myelofibrosis patients transformed to leukemia.

AB - Transformed acute myeloid leukemia in myelofibrosis results in a median survival of less than 5 months. We identified 46 of 1048 myelofibrosis patients in the European Group for Blood and Marrow Transplantation registry who received allogeneic stem cell transplantation for acute leukemia evolving from myelofibrosis. The cumulative incidence of treatment-related mortality at 1 year was 28% (95% confidence interval, 14 to 42) and of relapse at 3 years was 47% (95% confidence interval, 31 to 63). The 3-year progression-free (PFS) and overall survival (OS) rates were 26% and 33%, respectively. The only significant factor for survival was complete remission versus no complete remission before transplantation (69% versus 22%, P = .008); however, complete remission was achieved only in 8 patients. Allogeneic stem cell transplantation can cure myelofibrosis patients transformed to leukemia.

KW - Adult

KW - Aged

KW - Cohort Studies

KW - Europe

KW - Female

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - Leukemia, Myeloid, Acute

KW - Male

KW - Middle Aged

KW - Myeloproliferative Disorders

KW - Neoplasm Recurrence, Local

KW - Primary Myelofibrosis

KW - Remission Induction

KW - Transplantation Conditioning

KW - Transplantation, Autologous

U2 - 10.1016/j.bbmt.2013.10.027

DO - 10.1016/j.bbmt.2013.10.027

M3 - SCORING: Journal article

C2 - 24201159

VL - 20

SP - 279

EP - 281

JO - BIOL BLOOD MARROW TR

JF - BIOL BLOOD MARROW TR

SN - 1083-8791

IS - 2

ER -